RIGEL PHARMACEUTICALS INC (RIGL) Stock Fundamental Analysis

NASDAQ:RIGL • US7665597024

35.72 USD
+0.17 (+0.48%)
At close: Feb 18, 2026
36 USD
+0.28 (+0.78%)
After Hours: 2/18/2026, 4:30:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

Taking everything into account, RIGL scores 7 out of 10 in our fundamental rating. RIGL was compared to 521 industry peers in the Biotechnology industry. RIGL is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. RIGL is evaluated to be cheap and growing strongly. This does not happen too often! This makes RIGL very considerable for value and growth investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year RIGL was profitable.
  • RIGL had a positive operating cash flow in the past year.
  • RIGL had negative earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
RIGL Yearly Net Income VS EBIT VS OCF VS FCFRIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • With an excellent Return On Assets value of 46.72%, RIGL belongs to the best of the industry, outperforming 99.42% of the companies in the same industry.
  • RIGL has a better Return On Equity (96.34%) than 99.42% of its industry peers.
  • RIGL has a Return On Invested Capital of 63.44%. This is amongst the best in the industry. RIGL outperforms 99.62% of its industry peers.
Industry RankSector Rank
ROA 46.72%
ROE 96.34%
ROIC 63.44%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RIGL Yearly ROA, ROE, ROICRIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

  • RIGL's Profit Margin of 40.17% is amongst the best of the industry. RIGL outperforms 96.93% of its industry peers.
  • With an excellent Operating Margin value of 42.17%, RIGL belongs to the best of the industry, outperforming 98.85% of the companies in the same industry.
  • RIGL's Gross Margin of 93.10% is amongst the best of the industry. RIGL outperforms 93.67% of its industry peers.
  • In the last couple of years the Gross Margin of RIGL has declined.
Industry RankSector Rank
OM 42.17%
PM (TTM) 40.17%
GM 93.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
RIGL Yearly Profit, Operating, Gross MarginsRIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), RIGL is creating value.
  • RIGL has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for RIGL has been reduced compared to 5 years ago.
  • RIGL has a better debt/assets ratio than last year.
RIGL Yearly Shares OutstandingRIGL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RIGL Yearly Total Debt VS Total AssetsRIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -0.98, we must say that RIGL is in the distress zone and has some risk of bankruptcy.
  • RIGL has a Altman-Z score of -0.98. This is comparable to the rest of the industry: RIGL outperforms 57.20% of its industry peers.
  • RIGL has a debt to FCF ratio of 0.88. This is a very positive value and a sign of high solvency as it would only need 0.88 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 0.88, RIGL belongs to the best of the industry, outperforming 93.67% of the companies in the same industry.
  • RIGL has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
  • RIGL has a worse Debt to Equity ratio (0.25) than 65.83% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for RIGL, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.88
Altman-Z -0.98
ROIC/WACC7.15
WACC8.87%
RIGL Yearly LT Debt VS Equity VS FCFRIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 2.28 indicates that RIGL has no problem at all paying its short term obligations.
  • RIGL has a worse Current ratio (2.28) than 72.94% of its industry peers.
  • RIGL has a Quick Ratio of 2.14. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of RIGL (2.14) is worse than 72.36% of its industry peers.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.14
RIGL Yearly Current Assets VS Current LiabilitesRIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 4307.14% over the past year.
  • RIGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 79.13%.
  • Measured over the past years, RIGL shows a very strong growth in Revenue. The Revenue has been growing by 24.77% on average per year.
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%

3.2 Future

  • RIGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 38.70% yearly.
  • RIGL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.91% yearly.
EPS Next Y617.8%
EPS Next 2Y102.8%
EPS Next 3Y73.32%
EPS Next 5Y38.7%
Revenue Next Year68.61%
Revenue Next 2Y26.11%
Revenue Next 3Y22.67%
Revenue Next 5Y15.91%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RIGL Yearly Revenue VS EstimatesRIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
RIGL Yearly EPS VS EstimatesRIGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 5.79, the valuation of RIGL can be described as very cheap.
  • Compared to the rest of the industry, the Price/Earnings ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 99.04% of the companies listed in the same industry.
  • RIGL's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.16.
  • With a Price/Forward Earnings ratio of 9.24, the valuation of RIGL can be described as very reasonable.
  • RIGL's Price/Forward Earnings ratio is rather cheap when compared to the industry. RIGL is cheaper than 98.08% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.10, RIGL is valued rather cheaply.
Industry RankSector Rank
PE 5.79
Fwd PE 9.24
RIGL Price Earnings VS Forward Price EarningsRIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 99.23% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, RIGL is valued cheaper than 98.66% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.51
EV/EBITDA 3.95
RIGL Per share dataRIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • RIGL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • RIGL has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as RIGL's earnings are expected to grow with 73.32% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y102.8%
EPS Next 3Y73.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for RIGL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGL (2/18/2026, 4:30:02 PM)

After market: 36 +0.28 (+0.78%)

35.72

+0.17 (+0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)03-02
Inst Owners85.11%
Inst Owner Change6.21%
Ins Owners2.59%
Ins Owner Change-4.81%
Market Cap648.32M
Revenue(TTM)282.08M
Net Income(TTM)113.30M
Analysts80
Price Target47.94 (34.21%)
Short Float %21.09%
Short Ratio8.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)3.68%
PT rev (3m)22.61%
EPS NQ rev (1m)17.09%
EPS NQ rev (3m)32.38%
EPS NY rev (1m)0.92%
EPS NY rev (3m)19.02%
Revenue NQ rev (1m)3.4%
Revenue NQ rev (3m)4.28%
Revenue NY rev (1m)0.51%
Revenue NY rev (3m)4.02%
Valuation
Industry RankSector Rank
PE 5.79
Fwd PE 9.24
P/S 2.3
P/FCF 9.51
P/OCF 9.51
P/B 5.51
P/tB 7.03
EV/EBITDA 3.95
EPS(TTM)6.17
EY17.27%
EPS(NY)3.87
Fwd EY10.82%
FCF(TTM)3.75
FCFY10.51%
OCF(TTM)3.76
OCFY10.52%
SpS15.54
BVpS6.48
TBVpS5.08
PEG (NY)0.01
PEG (5Y)N/A
Graham Number29.99
Profitability
Industry RankSector Rank
ROA 46.72%
ROE 96.34%
ROCE 80.3%
ROIC 63.44%
ROICexc 854.98%
ROICexgc N/A
OM 42.17%
PM (TTM) 40.17%
GM 93.1%
FCFM 24.16%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.88
Debt/EBITDA 0.25
Cap/Depr 1.57%
Cap/Sales 0.01%
Interest Coverage 17.61
Cash Conversion 56.17%
Profit Quality 60.14%
Current Ratio 2.28
Quick Ratio 2.14
Altman-Z -0.98
F-Score7
WACC8.87%
ROIC/WACC7.15
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
EPS Next Y617.8%
EPS Next 2Y102.8%
EPS Next 3Y73.32%
EPS Next 5Y38.7%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
Revenue Next Year68.61%
Revenue Next 2Y26.11%
Revenue Next 3Y22.67%
Revenue Next 5Y15.91%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year546.96%
EBIT Next 3Y91.91%
EBIT Next 5Y95.89%
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A

RIGEL PHARMACEUTICALS INC / RIGL FAQ

What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?

ChartMill assigns a fundamental rating of 7 / 10 to RIGL.


What is the valuation status for RIGL stock?

ChartMill assigns a valuation rating of 9 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.


Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?

RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.


How financially healthy is RIGEL PHARMACEUTICALS INC?

The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 7 / 10.